Wave Life Sciences (WVE) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.30
- Estimate
- -$0.32
- Surprise
- +7.3%
- Revenue (period 2026-09-30)
- $13.2M
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
Wave Life Sciences (WVE) reported a narrower loss than forecast — adjusted EPS of -$0.30 against the -$0.32 estimate (a 7.3% beat on a still-unprofitable quarter).
Coverage in the report window
- Canaccord Genuity Maintains Buy on Wave Life Sciences, Raises Price Target to $44 — benzinga, 2026-10-29
- Oppenheimer Adjusts Price Target on Wave Life Sciences to $29 — fiscal.ai, 2026-10-28
- Oppenheimer Maintains Outperform on Wave Life Sciences, Lowers Price Target to $29 — benzinga, 2026-10-28
Where TrendMatrix's rating stands now
TrendMatrix currently rates WVE Sell at 5.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +7.3% surprise compares with a +9.5% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $16.63 vs price $2.87 — ratio 5.8×). Rejected, falling back to technical TP.
- Quality below floor (2.5 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 4.6), Material insider selling (11 sells, 0.06% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $2.87
- Price target
- $3.78
- Stop
- $2.76
- Upside to target
- +31.7%
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
WVE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $617.3M
- P/E (fwd)
- -2.7
- 52-week range
- $3.00–$21.73
- Off 52-week high
- 86.8%
- RSI (14)
- 33
- Volume vs avg
- 0.78×
- Score today
- 5.6/10